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Abstract
Background: Among the numerous genetic defects associated with hepatocarcinogenesis, telomere abnormalities
appear to play a role both in tumor promotion and maintenance. Telomeres, the chromosome extremities, are
protected by specific proteins, the shelterin complex and by additional factors. Besides telomerase dysregulation,
expression changes of these telomere factors have been observed in cancers.
Methods: Here, we tested the hypothesis that such dysregulation might occur in hepatocellular carcinoma (HCC) with
specific patterns depending on the cause of HCC. We compared telomere length, telomerase activity (TA), hTERT and
telomere genes expression using PCR and Western-blot analyses between non-cirrhotic liver, peritumoral cirrhotic
tissue (40 samples) and cancerous tissue (40 samples) derived from 40 patients with HBV-, HCV-, or alcohol-related HCC.
Results: Alterations in TA, hTERT expression and telomere length between non-cirrhotic, cirrhotic, and tumor samples
were not significantly influenced by the cause of HCC. In contrast, the expression pattern of hTR, shelterin, and non-
shelterin telomere protective factors clearly distinguished the 3 causes of cirrhosis and HCC. For patients with HBV
diseased liver, when compared with non-cirrhotic liver, the cirrhotic tissue underexpressed all shelterin and all but
HMRE11A and RAD50 non-shelterin telomere factors. For HCV the expression level of POT1, RAP1, Ku80, and RAD50 was
higher in cirrhotic than in non-cirrhotic liver samples without evidence for significant transcriptional change for the
remaining genes. For alcohol-related liver diseases, the expression level of POT1, RAP1, TIN2, hMRE11A, hMRE11B, Ku70,
Ku80, RAD50, TANK1, and PINX1 was higher in cirrhotic than in non-cirrhotic liver samples. For the 3 causes of HCC, there
was no significant change in shelterin and non-shelterin gene expression between cirrhosis and HCC samples.
Conclusions: These results validate our hypotheses and demonstrate that cirrhosis and HCC add-up numerous
telomere dysfunctions including numerous cause-specific changes that appear to occur early during the course of
the disease.
Keywords: Liver, Hepatocellular carcinoma, Telomere, Telomerase, Shelterin, Hepatitis B virus, Hepatitis C virus, Alcohol,
Cirrhosis
Background
Hepatitis B (HBV) or C virus (HCV) infection and alcohol
consumption are leading causes of hepatocellular carcin-
oma (HCC) that predominantly develops from chronic
hepatitis and cirrhosis [1]. Among the numerous genetic
and epigenetic defects associated with carcinogenesis [2],
telomere abnormalities play a role in tumor promotion
and maintenance [3-9]. Telomeres, the chromosome
extremities, are elongated by the human telomerase, the
catalytic moiety of which is encoded by the human
telomerase reverse transcriptase (hTERT) gene [10]. Add-
itionally, telomeres are protected by specific proteins, the
shelterin complex [11] and by additional non-specific fac-
tors such as human meiotic recombination 11 homolog A
and B (hMRE11A and B), Ku proteins 70 and 80 (Ku70
and Ku80), Nijmegen breakage syndrome-1 (NBS1),
RAD50, tankyrase 1 and 2 (TANK1 and 2), Werner
syndrome helicase (WRN), and PIN2/TRF1-interacting,
telomerase inhibitor 1 (PINX1) [12]. These factors prevent
telomere degradation and facilitate telomerase-based telo-
mere elongation.
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Short or unprotected telomeres are recombinogenic
and can therefore promote tumorigenesis [3]. In normal
cells, dysfunctional telomeres trigger the DNA damage
response and replicative cellular senescence [10,13-18].
Early oncogenic events frequently involve evasion of the
DNA damage response, which allows the clonal persist-
ence of cells bearing a telomere-associated genetic in-
stability. During early tumor development, hTERT is
frequently expressed and allows the clone to bypass mi-
totic catastrophe and replicative senescence, contribut-
ing to malignant immortalization [4,5,19-21]. Therefore,
impaired telomere protection and/or elongation repre-
sent putative oncogenic events. Indeed, numerous onco-
genes or tumor suppressor genes have been reported to
interfere with the telomere machinery. In the liver, telo-
mere shortening correlates with chromosomal instability
and the development of HCC [4,6,8]. Hepatotropic viruses
and alcohol have been reported to interfere with telomere
homeostasis. For example, hTERT transcription was found
to be activated upon HBV DNA integration in the vicinity
of the hTERT gene [22] while HBV encoded X (HBx)
[23-27] or preS2 [28,29] proteins promote hTERT expres-
sion and contributed to clonal persistence. However, some
mutated HBx have been reported to possess repressive ef-
fects on hTERT transcription [25]. The HCV core protein
has been demonstrated to enhance telomerase activity
[30] while alcohol exposure triggers premature senescence
with accelerated telomere shortening [31].
Changes in telomere length, telomerase activity and
hTERT expression have been extensively explored at differ-
ent steps of hepatocarcinogenesis. However, to our know-
ledge, the status of shelterin and non-shelterin telomere
factors has not been examined during liver carcinogenesis.
Furthermore, little is known about the interactions be-
tween telomere alterations and the cause of HCC, although
hepatitis viruses and alcohol are known to possess specific
and distinct effect on telomere homeostasis in vitro
[22,23,25-29,31]. Dissecting telomere factors’ deregulation
during carcinogenesis has revealed novel oncogenic path-
ways, prognostic markers, and therapeutic targets aimed at
preventing or treating cancers. The aim of this study was
to determine whether the main causes of HCC might
trigger distinct telomere effects in vivo.
Methods
Samples
The medical ethics committee of the Hospices Civils de
Lyon approved the study, and the informed consent was
obtained from patients in accordance with the Declaration
of Helsinki and with institutional guidelines. The study
population consisted of paired tumor and non-tumor
tissues from 40 patients suffering from HCC including 10
HBV-, 10 HCV-, 10 alcohol-related and 10 HCC without
HCV viral or alcohol exposure (idiopathic HCC).
Serological markers for HBV (HBsAg, HBeAg and anti-
HBe), HCV (anti-HCV) were tested in all cases by
commercial enzyme immunoassays. The clinical and
histological data accompanying the samples analyzed
are shown in Table 1. Tissue samples from patients
resected for HCC were collected during surgery and
divided into two parts: one was immediately cut into
small pieces, snap-frozen in liquid nitrogen and stored
in deep freezer; the other was fixed in 10% formalin and
paraffin-embedded for histopathological examination
and immunohistochemistry. Histological analysis and
immunohistochemistry were performed at the Depart-
ment of Pathology at the Hospices Civils de Lyon.
Telomere length assay
Each sample was homogenized and total cellular DNA was
extracted using phenol chloroform. The average telomere
length was measured in all samples using the TeloTAGGG
Telomere length Assay (Roche). Briefly, purified genomic
DNA (6–8 μg) was digested by specific restriction enzymes.
The DNA fragments were separated by gel electrophoresis
and transferred to a nylon membrane using Southern
blotting. The blotted DNA fragments were hybridized to a
digoxigenin-labeled probe specific to telomere repeats and
incubated with a digoxigenin-specific antibody coupled to
alkaline phosphate. Finally, the immobilized probe was
visualized by a sensitive chemiluminescence substrate and
the average TRF length was assessed by comparing the
signals relative to a molecular weight standard.
Quantification of telomerase activity
The telomeric repeats amplification protocol (TRAP) was
combined with real-time detection of amplification prod-
ucts to determine telomerase activity using a Quantitative
Telomerase Detection kit (US Biomax) following the manu-
facturer’s recommendations. Total protein extracts (0.5 μg)
were used for each reaction. The end products were
resolved by PAGE on a 12.5% non-denaturing gel, stained
with Sybr Green Nucleic Acid gel stain (Invitrogen) and
visualized using the Bio-Rad Molecular Imager ChemiDoc
System.
Real-time quantitative reverse transcriptase-polymerase
chain reaction (PCR)
Each tissue sample was homogenized and total cellular
RNA was extracted using the MasterPure Complete DNA
and RNA Purification Kit (Epicentre) according to the
manufacturer’s instructions. Before reverse transcription,
RNA was treated with DNase (Invitrogen-Life technology)
to prevent DNA contamination. First-strand complemen-
tary DNA (cDNA) was synthesized from 0.5 μg RNA
using random primers (Promega) and Superscript II
reverse transcriptase (Invitrogen). The RNA concentration
and purity were determined using a NanoDrop instrument
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(Thermo Scientific). The primer sequences are available
upon request. Primer sets used to quantify gene expres-
sion were first tested in PCR with a control cDNA to
ensure specific amplification, as evidenced by the pres-
ence of a unique specific signal after agarose gel electro-
phoresis. PCR assays were performed on an ABI Prism
7000 sequence detection system (Applied Biosystems)
using 5 μL of cDNA, 6 μL of SYBR Green Master Mix,
0.25 μL of ROX (Invitrogen) and 0.75 μL of primers
at 10 μM. Thermal cycling consisted of a first cycle at
50°C for 2 min and 95°C for 10 min, followed by 40 cy-
cles at 95°C for 15 seconds and 60°C for 1 min. Finally
at the end of each PCR run, temperature was raised up
to 95°C in order to check the melting curve. The ex-
pression of each gene of interest was normalized against
2 housekeeping genes, Gus (NM_000181) and ERCC1
(NM_001983), which have been validated using the
BestKeeper software tool [32] to adjust for variations in
RNA amount and cDNA synthesis. The relative quanti-
fication was depicted as the fold-change in expression
of each gene using the formula 2ΔΔCt, as previously
described [33]. Each assay was performed in duplicate.
Western blot analysis
The antibodies to MRE11 were purchased from Santa Cruz
Biotechnology (Sc-22,767), hTERT (ab-32,020) and POT1
(ab-124,784) were purchased from Abcam, TRF2 (05-521)
was purchased from Millipore, and the antibodies to Ku80
(2753S) and beta-Actin (4967S) were purchased from Cell
Signaling Technology. Tumor extracts were homogenized
and then lysed. The protein concentration was determined
using the Bio-rad Dc Protein Assay Kit (Bio-rad). Equal
amounts of proteins were subjected to sodium dodecyl sul-
fate 10% polyacrylamide gel electrophoresis (MiniProtean
TGX, BioRad) and fractionated proteins were transferred
to PVDF membranes (Transblot Turbo, BioRad). These
membranes were blocked in TBS containing 5% nonfat
milk, 0.05% Tween 20, and then probed with the appropri-
ate antibody followed by incubation with a secondary IgG
HRP-linked antibody (Cell Signaling Technology). The
blots were then developed using an enhanced chemilumin-
escence detection system (Clarity Western ECL, BioRad).
Immunocytochemistry
Ki67 was assessed using the anti-Ki67 MoAbs (clone MIB-
1 Dako, on BenchMark Ventana XT). CC1 treatment
(1/50) was performed before ultraview revelation. Ki67
Table 1 Clinical features of the 40 patients with
hepatocellular carcinoma
UPN Age Sex Serological markers Peritumoral
histology
HBV HCV
HBV-associated hepatocellular carcinoma
1 65 M + - Cirrhotic
2 58 M + - Cirrhotic
3 35 F + - Normal
4 47 M + - Normal
5 58 M + - Cirrhotic
6 50 F + - Cirrhotic
7 60 M + - Cirrhotic
8 33 M + - Cirrhotic
9 74 M + - Cirrhotic
10 44 M + - Cirrhotic
HCV-associated hepatocellular carcinoma
11 56 M - + Cirrhotic
12 68 M - + Cirrhotic
13 58 M - + Cirrhotic
14 61 F - + Cirrhotic
15 55 M - + Cirrhotic
16 57 M - + Cirrhotic
17 73 M - + Cirrhotic
18 70 M - + Cirrhotic
19 47 M - + Normal
20 66 M - + Cirrhotic
Alcohol-associated hepatocellular carcinoma
21 49 F - - Cirrhotic
22 56 M - - Cirrhotic
23 49 M - - Cirrhotic
24 83 M - - Cirrhotic
25 59 M - - Cirrhotic
26 58 M - - Cirrhotic
27 62 F - - Cirrhotic
28 58 M - - Cirrhotic
29 63 M - - Cirrhotic
30 59 M - - Cirrhotic
Idiopathic hepatocellular carcinoma
31 45 M - - Normal
32 66 M - - Normal
33 72 F - - Normal
34 72 M - - Normal
35 75 F - - Normal
36 76 M - - Cirrhotic
37 35 M - - Normal
Table 1 Clinical features of the 40 patients with
hepatocellular carcinoma (Continued)
38 67 M - - Normal
39 72 F - - Normal
40 78 M - - Normal
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immunohistochemistry was quantified by a pathologist.
The percentage of labeled nuclear area over the total neo-
plastic and the non-neoplastic nuclear area in the section
was quantified from 2000 cells in areas of highest nuclear
labeling.
Statistical analysis
Statistical analysis was performed using the 2-tailed
Student’s t test or the Mann–Whitney U rank sum test.
P < 0.05 was considered statistically significant in all
analyses. All data analyses were performed using SPSS
statistical software version 20.
Results
The main objective of this study was to determine whether
differences exist in telomere deregulation between HBV-,
HCV-, and alcohol-associated liver carcinogenesis. Liver
carcinogenesis is a multistep process where clinical and
histopathological features frequently permits the differen-
tiation of the two main phases that include a cirrhotic
stage followed by the development of overt HCC. Our col-
lection of 80 liver samples was obtained from 40 patients
with HCC. For each case 2 samples were analyzed that
corresponded to tumoral and peritumoral tissue. The
Table 1 shows that in 12 cases of HCC, peritumoral sam-
ples corresponded to histologically normal, non-cirrhotic
liver tissue whereas in the 28 remaining cases, the
peritumoral tissue was cirrhotic. We assumed that the de-
velopment of cirrhosis from a histologically non-cirrhotic
liver represents an early event during liver carcinogenesis,
whereas the development of HCC from a cirrhotic liver
reflects later carcinogenic events. Accordingly, in order to
assess telomere dysregulation at the early and late stages
of liver carcinogenesis, we compared cell proliferation,
Telomere Restriction Fragment (TRF) length, TA, hTERT,
human telomerase RNA compound (hTR), shelterin and
non-shelterin telomere factor expression between non-
cirrhotic and cirrhotic liver samples and between cirrhotic
and HCC liver samples for each cause of HCC (Additional
file 1: Table S1, Additional file 2: Table S2. Figure 1 repre-
sents the distribution of TRF length, hTERT and hTR ex-
pression, TA (Figure 1A) and telomere factors expression
(Figure 1B) in peritumoral and tumoral samples derived
from patients suffering from idiopathic, HBV-, HCV-, and
alcohol-related HCC. Figure 2 represents the expression
of Ki67 (Figure 2A), hTERT (Figure 2B) and telomere
protective factors (Figure 2B and C) at the protein level.
Telomere deregulation at the early stage of
HBV-associated hepatocarcinogenesis
Expression of the proliferative marker Ki67 was not sig-
nificantly different between the 8 HBV positive cirrhotic
samples and the 12 non-cirrhotic liver samples deriving
from patients with HCC. As illustrated in Figure 1A, the
level of hTERT expression was significantly higher in the
8 HBV positive cirrhotic samples than in the 12 non-
cirrhotic liver samples (p = 0.040, Mann–Whitney test).
In contrast, there was no significant difference in the
level of TA between the cirrhotic and non-cirrhotic sam-
ple categories. HBV-associated cirrhosis expressed signifi-
cantly lower hTR levels when compared to histologically
non-cirrhotic liver tissue: 0.0053 versus 0.3574 arbitrary
units (p < 10-4, Mann–Whitney test) (Figure 1A). The TRF
length was longer in HBV positive cirrhotic samples than
in non-cirrhotic samples (6.60 kbp versus 5.69 kbp) but
the difference was not statistically significant. Comparative
Western-blot analysis of hTERT expression in HBV posi-
tive cirrhotic samples versus non-cirrhotic liver samples
confirmed the qRTPCR results for hTERT expression
(Figure 2B). Table 2 and Figure 1B show that all shelterin
and non-shelterin telomere factors except HMRE11A and
RAD50 were significantly underexpressed in HBV positive
peritumoral cirrhotic samples. Comparative Western-blot
analysis confirmed that protection of telomeres 1 (POT1),
telomere repeat factor 2 (TRF2), HMR11A/B, and Ku80
had lower expression levels in HBV positive cirrhotic
samples than in non-cirrhotic liver samples (Figure 2C
and D). These results suggest that at the telomere level,
the development of HBV-associated cirrhosis includes
strong hTERT overexpression and considerable repres-
sion of hTR, shelterin, and non-shelterin telomere fac-
tors. Similar results were obtained when the 8 HBV+
cirrhotic samples were compared with the 9 non-
cirrhotic liver samples derived from patients with
idiopathic HCC (data not shown).
Telomere deregulation at the early stage of
HCV-associated hepatocarcinogenesis
Expression of the Ki67 proliferation marker was not
significantly different between the 9 HCV positive cir-
rhotic samples and the 12 non-cirrhotic liver samples
deriving from patients with HCC. There was no signifi-
cant difference in the expression level of TA, hTERT
and hTR between the two sample categories (Figure 1A).
Western-blot analysis of hTERT expression confirmed
the qRTPCR results for hTERT expression (Figure 2B).
Shelterin, POT1 and repressor-activator protein 1 (RAP1)
were demonstrated to be significantly overexpressed in
HCV positive cirrhotic samples when compared with non-
cirrhotic liver samples. The remaining factors displayed an
identical (TRF2) or a non-significant reduced expression
level (Table 2). In contrast to HBV, all telomere factors ex-
cept Pinx1 non-shelterin were overexpressed in cirrhotic
peritumoral HCV positive samples, as compared to non-
cirrhotic liver samples (Figure 1C, Table 2). Indeed, the
expression of Ku80 (p = 0.029) and RAD50 (p = 0.018) was
approximately 3 times higher than that of the control sam-
ples. Western-blots confirmed that POT1, HMRE11A/B,
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and KU80 were more expressed in HCV positive cirrhotic
samples than in non-cirrhotic liver samples (Figure 2D).
These results suggested that at the telomere level, the
main changes that accompany the development of
HCV-associated cirrhosis predominately involve the
overexpression of POT1, RAP1, Ku80, and RAD50 telo-
mere factors.
Telomere deregulation at the early stage of
alcohol-associated hepatocarcinogenesis
Expression of the Ki67 proliferative marker was not sig-
nificantly different between alcohol-associated cirrhotic
and non-cirrhotic liver tissues deriving from patients with
HCC. There was no significant difference in TRF length,
TA, hTERT and hTR expression between the two sample
(See figure on previous page.)
Figure 1 Common and specific telomere abnormalities between HBV-, HCV-, and alcohol-associated cirrhosis and hepatocellular
carcinoma. A. Distribution of hTERT and hTER expression, telomerase activity and TRF length among the main causes of hepatocellular carcinoma.
B. Alteration in shelterin and non-shelterin gene expression at the two main steps of liver carcinogenesis in vivo. Significantly overexpressed
genes (p < 0.05, Mann Whitney test) are represented in black whereas significantly underexpressed genes are represented in gray.
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Figure 2 Immunohistochemistry and Western-blot analysis. (A) Ki67, (B) hTERT, (C,D) shelterin and non-shelterin and (D) telomere factors in
the main causes of cirrhosis and hepatocellular carcinoma.
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categories (Figure 1A). Western-blot analysis of hTERT
expression confirmed the qRTPCR results (Figure 2B).
Shelterin, POT1 (p = 0.005) and RAP1 (p = 0.006) were
demonstrated to be significantly overexpressed in alcohol-
associated cirrhotic tissues, whereas other shelterins were
found to be underexpressed, with TRF1-interacting nu-
clear protein 2 gene (TIN2) showing a significant differ-
ence (Table 2). All non-shelterin telomere factors,
except TANK2 and Pinx1, contained a transcriptional
pattern that resembled that in HCV cirrhotic samples.
Accordingly, all telomere factors except the TANK2
non-shelterin were overexpressed in cirrhotic alcohol-
exposed liver with significant differences demonstrated
for HMRE11A, HMRE11B, Ku70, Ku80, RAD50, TANK1,
and Pinx1 (Table 2, Figure 1C). Western-blot analyses con-
firmed the qRTPCR results for POT1, TRF2, HMR11A/B,
and KU80 (Figure 2C and D). These results suggested that
at the telomere level, the main changes accompanying the
development of alcohol-associated cirrhosis and fibrosis
predominantly involve the overexpression of POT1, RAP1,
HMRE11A, HMRE11B, Ku70, Ku80, RAD50, TANK1, and
Pinx1 telomere factors. Taken together, these results indicate
that the development of HBV-, HCV-, and alcohol-related
cirrhosis rely on clearly distinct telomere perturbations and
suggests that these distinct carcinogens possess specific
effects on telomere homeostasis. Consequently, 3 kinds of
cirrhotic tissues displayed significant differences in the
expression of telomere factors (Figure 1, Additional file 3:
Table S3).
Telomere deregulation at the late stage of
HBV-associated hepatocarcinogenesis
Having demonstrated the cause-specific changes in telo-
mere factors’ expression between cirrhotic and non-
cirrhotic livers, i.e. during early hepatocarcinogenesis,
we next sought to investigate whether these differences
persist at the late stages of HCC development. To this
end we compared telomere deregulations between cir-
rhotic and tumoral samples deriving from patients with
HCC. We first compared the 10 HBV-associated HCC
samples with their 8 cirrhotic peritumoral samples.
Expression of the Ki67 proliferative marker was signifi-
cantly increased in HBV-associated HCC, as compared
with HBV-associated cirrhosis (p = 0.002, Mann–Whitney
test). The TRF length was significantly shorter in tumor
samples than in cirrhotic samples (p = 0.05, Mann–
Whitney test) whereas the levels of TA and hTERT ex-
pression were significantly higher in HBV positive HCC
(p = 0.017 for hTERT and p = 0.002 for TA, Mann–
Whitney test) without any significant difference in the
level of hTR expression between the 2 tissues (Figure 1A).
Western-blotting analyses confirmed the qRTPCR results
for hTERT expression (Figure 2B). Table 3 shows that with
the exception of Pinx1, where there was a trend for higher
expression in HCC, all shelterin and non-shelterin genes
remained underexpressed in HBV positive HCC without
any significant difference between cirrhosis and HCC.
Western-blot analysis of TRF2, HMRE11A/B, Ku80, and
POT1 confirmed the qRTPCR results (Figure 2C and D).
Table 2 Cause-specific differences in telomeric gene expression between cirrhotic and non-cirrhotic liver samples
Non-cirrhotic Cirrhotic p
(n = 12) HBV (n = 8) HCV (n = 9) Alcohol (n = 10) For HBV For HCV For alcohol
Shelterin
POT1 0.0021 0.0000 0.0125 0.0090 0.0480 0.0100 0.0050
PTOP 0.0094 0.0000 0.0037 0.0055 0.0200 ns ns
RAP1 0.1570 0.0016 0.4210 0.4091 0.0070 0.0080 0.0060
TIN2 0.3510 0.0018 0.0510 0.0804 0.0010 ns <10-4
TRF1 0.5585 0.0117 0.2271 0.2488 <10-4 ns ns
TRF2 0.0016 0.0000 0.0016 0.0012 0.0050 ns ns
Non-Shelterin
HMRE11A 0.0187 0.0006 0.0627 0.0764 ns ns 0.0070
HMRE11B 0.0359 0.0008 0.0492 0.0886 0.0030 ns 0.0020
Ku70 0.0955 0.0045 0.1704 0.1825 <10-4 ns 0.0440
Ku80 0.0408 0.0033 0.1209 0.1316 0.0200 0.0290 0.0120
NBS1 0.0266 0.0002 0.0304 0.0403 0.0030 ns ns
RAD50 0.0030 0.0002 0.0091 0.0108 ns 0.0180 0.0500
TANK1 0.0468 0.0005 0.0788 0.0945 <10-4 ns 0.0030
TANK2 0.0129 0.0000 0.0188 0.0127 0.0200 ns ns
Pinx1 0.0131 0.0001 0.0083 0.0219 0.0020 ns 0.0210
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These results suggested that at the telomere level, aug-
mented TA and hTERT expression represent the major
significant telomere deregulation distinguishing HBV-
associated HCC from HBV-associated cirrhosis. Accord-
ingly, comparison of HBV-related HCC with non-cirrhotic
liver samples demonstrated similar differences as the com-
parison of HBV-related cirrhosis with non-cirrhotic liver
samples (Additional file 4: Table S4).
Telomere deregulation at the late stage of
HCV-associated hepatocarcinogenesis
HCV-associated HCC expressed higher levels of the
Ki67 proliferative marker (6% versus 1%) than peri-
tumoral cirrhotic tissue samples but the difference
was not statistically significant. When compared to
their peritumoral cirrhotic tissue samples, HCV positive
HCC expressed higher amounts of hTERT transcripts
(p = 0.54) and hTR (p = 0.021) and they displayed in-
creased TA (p = 0.036) when compared with HCV posi-
tive cirrhosis (Figure 1A). The TRF length was shorter
in HCV-associated cirrhosis than in HCC but the differ-
ence was not statistically significant (5.1 kbp versus 6.6
kbp, p = 0.39) (Figure 1A). Table 3 shows that the pat-
tern of shelterin and non-shelterin genes expression
was not significantly different between HCV-associated
HCC and HCV-associated cirrhosis. Western-blot ana-
lysis confirmed qRTPCR results (Figure 2B,C, and D).
These results suggested that at the telomere level,
increased TA and hTR expression represent the major
significant telomere deregulation that distinguishes
HCV-associated HCC from HCV-associated cirrhosis.
Telomere deregulation at the late stage of
alcohol-associated hepatocarcinogenesis
When compared to their peritumoral cirrhotic tissue
samples, alcohol-associated HCC expressed higher
levels of the Ki67 proliferative marker (8% versus 1%)
but the difference was not statistically significant.
Figure 1A shows that TA, hTERT and hTR expressions
were augmented in alcohol-associated HCC but these
differences were not statistically significant. Table 3
shows that the pattern of shelterin and non-shelterin
genes expression was not significantly different be-
tween alcohol-associated HCC and alcohol-associated
cirrhosis. Western-blot analysis confirmed the qRTPCR
results (Figure 2C and D). These results suggested that
at the telomere level, there is no significant deregula-
tion that distinguishes alcohol-associated HCC from
alcohol-associated cirrhosis.
Discussion
The data suggest that the development of HCC involves
the accumulation of numerous telomere dysfunctions
that appear to include cause-specific deregulations. Our
sample collection permitted the comparison of histologi-
cally non-cirrhotic livers with cirrhosis and HCC in the
context of HBV and HCV infections, and alcohol expos-
ure. Given that HCC mostly develop from cirrhotic
Table 3 Cause-specific differences in telomeric gene expression between cirrhotic/fibrotic and HCC tissue samples
HBV HCV Alcohol
Cirrhotic and/or
Fibrotic (n = 8)
HCC (n = 10) p Cirrhotic and/or
Fibrotic (n = 9)
HCC (n = 10) p Cirrhotic and/or
Fibrotic (n = 10)
HCC (n = 10) p
Shelterin
POT1 0.0000 0.0000 ns 0.0125 0.0203 ns 0.0090 0.0060 ns
PTOP 0.0000 0.0000 ns 0.0037 0.0064 ns 0.0055 0.0071 ns
RAP1 0.0016 0.0000 ns 0.4210 0.5059 ns 0.4091 0.2538 ns
TIN2 0.0018 0.0033 ns 0.0510 0.0581 ns 0.0804 0.0876 ns
TRF1 0.0117 0.0209 ns 0.2271 0.1626 ns 0.2488 0.2886 ns
TRF2 0.0000 0.0000 ns 0.0061 0.0015 ns 0.0012 0.0012 ns
Non Shelterin
HMRE11A 0.0006 0.0000 ns 0.0627 0.0811 ns 0.0764 0.0536 ns
HMRE11B 0.0008 0.0000 ns 0.0492 0.0508 ns 0.0886 0.0850 ns
Ku70 0.0045 0.0024 ns 0.1704 0.2418 ns 0.1825 0.1645 ns
Ku80 0.0033 0.0015 ns 0.1209 0.1494 ns 0.1316 0.0853 ns
NBS1 0.0002 0.0024 ns 0.0304 0.0317 ns 0.0403 0.0501 ns
RAD50 0.0002 0.0000 ns 0.0091 0.0118 ns 0.0108 0.0101 ns
TANK1 0.0005 0.0000 ns 0.0788 0.0761 ns 0.0945 0.0869 ns
TANK2 0.0000 0.0006 ns 0.0188 0.0255 ns 0.0127 0.0171 ns
Pinx1 0.0001 0.0049 ns (0.054) 0.0083 0.0107 ns 0.0219 0.0165 ns
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livers, we assumed that comparing histologically non-
cirrhotic liver samples with cirrhotic liver samples would
reflect early carcinogenesis whereas comparing cirrhotic
liver samples with tumor samples would reflect later car-
cinogenic events. Indeed, alterations in TRF length, TA,
hTERT and hTR expression were identified at both the early
and late steps of hepatocarcinogenesis. These alterations
were observed roughly in parallel among the 3 different
causes of HCC. In contrast, the numerous changes demon-
strated in the expression of telomere protective factors
appeared to be restricted to early hepatocarcinogenesis.
Additionally, these changes permitted the identification of a
gene expression signature for each cause of cirrhosis and
HCC. There was furthermore, evidence that the telomere
phenotype of HBV-associated-cirrhosis and HCC was dif-
ferent from that of the other causes of cirrhosis and HCC.
No correlation was found between TA, hTERT expres-
sion and telomere length with respect to the cause of
cirrhosis and HCC. This result is in agreement with the
study of Saini et al. who compared TA, TRF and hTERT
expression between HBV, HCV, and non-B non-C-re-
lated HCC [34]. In contrast, Guo et al. reported that
HbsAg positive HCC expressed higher amounts of
hTERT mRNA than HbsAg negative HCC [35]. What-
ever the cause, there was no significant difference in
TRF length between cirrhotic and non-cirrhotic sam-
ples. This result was in agreement with the lack of differ-
ence in cell proliferation between the 2 samples categories,
as assessed by the quantification of Ki67 expression. In
contrast, the tumor samples expressed higher levels of the
Ki67 proliferative marker and contained shorter telomeres
than either non-cirrhotic or cirrhotic samples. There was
no precise correlation between the level of hTERT expres-
sion measured by qRTPCR and the level of TA measured
by the quantitative TRAP assay, suggesting that posttran-
scriptional modifications might participate to modulate TA
during hepatocarcinogenesis. Additionally, there was no
significant correlation between either hTERT expression or
TA and telomere length. Conversely, Figure 1A shows
that the shorter were the telomeres in sample sets, the
higher were TA and hTERT expression in these samples.
This conflicting data might be explained, at least in part,
by changes in regulating access of the telomere to the
telomerase in liver cells, i.e. by changes in telomere
proteins content.
Accumulating evidence suggests that telomeric factors
dysregulation is involved in cancer development as has
been demonstrated in the maintenance of the tumor
phenotype. To our knowledge, this study is the first which
investigates the expression of the main telomere protective
genes in the main subtype of cirrhosis and HCC. Previ-
ously, Oh et al. demonstrated that expression of TRF1,
TRF2 and TIN2 was gradually increased according to the
progression of hepatocarcinogenesis in HBsAg positive
individuals [36]. In this study, HBV-, HCV- and alcohol-
associated cirrhosis displayed significantly different distinct
patterns of telomere protective factor expression, as com-
pared with that of non-cirrhotic liver (Table 2). The 3 sub-
types of cirrhosis possessed a specific signature, with
respect to telomere protective factor expression (Additional
file 3: Table S3). Although the expression level of all the
shelterin and non-shelterin telomere factors was not
equally distributed between the 3 causes of cirrhosis
(Additional file 3: Table S3), the telomere phenotype of
HBV-associated-cirrhosis appeared different from that of
the 2 other causes of cirrhosis. When compared with non-
cirrhotic liver, HBV-associated cirrhosis displayed a dra-
matic repression of all shelterin and non-shelterin factors
except HMRE11A and RAD50. In contrast, the alterations
in telomere factor expression between non-cirrhotic and
cirrhotic samples were similar between HCV- and alcohol-
associated cirrhosis. Accordingly, the expression pattern of
all telomere factors, except TIN2 and HMRE11B, was
identical between HCV- and alcohol-associated cirrhosis
(Additional file 3: Table S3). These results suggest that
cause-specific factors are involved in initiating telomere
dysfunction in the liver. For example, HBV-associated cir-
rhosis displayed very low amounts of TRF2 that has been
demonstrated to elicit telomere shortening ex vivo [37].
Whatever the cause, the levels of shelterin and non-
shelterin telomere factors expression were not significantly
different between cirrhotic and HCC samples (Figure 1B
and Table 3). Again, the expression pattern of telomere
protective factor of HBV-associated-HCC remained dis-
tant from that of the 2 other causes of HCC, which closely
resembled that of idiopathic HCC (Additional file 5:
Table S5). This suggests that in HCC, the cause-specific
expression pattern of shelterin and non-shelterin factors
has been acquired early during the course of the disease.
Given that these factors are thought to prevent proper
telomerase-telomere interaction, the present results partly
explains the combination of high TA with short telomeres
in HCC.
Conclusion
In conclusion, the control of telomere homeostasis is
significantly dysregulated during liver carcinogenesis
and each cause of cirrhosis and HCC includes specific
dysregulation of telomere protective factors. These changes
occur early, at the cirrhotic stage, and persist to the tumor
stage, which suggests that they contribute to both tumor
development and tumor progression. By demonstrating
gene and protein dysregulation that are thought to prevent
proper telomerase-telomere interactions, the present results
partly explain the combination of high TA with short telo-
meres in HCC. Shortened and deprotected telomeres are
recombinogenic and contribute to the genetic instability
that characterize HCC and facilitate tumor progression,
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tumor recurrence and resistance to treatment [5-8,10]. Im-
portantly, hepatocytes have been reported to tolerate telo-
mere dysfunctions [37], reinforcing the tumorigenic impact
of alcohol-, HBV-, and HCV-associated telomere damage
in exposed individuals. Targeting telomerase is becoming a
promising approach for the treatment of HCC [38-40] and
our present results also support such an approach for
treating the main causes of this disease. In contrast, our
results suggest that targeting the cause-specific deregulation
of telomere protective factors might be of interest in the
prevention or the treatment of cirrhosis and HCC.
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